BioTime Company Profile - Sep 08, 2011 by WrightReports

VIEWS: 23 PAGES: 10

BioTime, Inc. is a biotechnology company engaged in two areas of biomedical research and product development. The Company's first business segment is blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment, and other applications. Its lead blood plasma expander product, Hextend, is a physiologically balanced intravenous solution used in the treatment of hypovolemia. Its second business segment is regenerative medicine. Regenerative medicine refers to therapies based on human embryonic stem (hES) cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. In October 2009, BioTime, Inc. initiated development programs for human therapeutic applications of hES cells, focused primarily on the treatment of cancer, ophthalmologic, skin, musculo-skeletal system, and hematologic diseases. Cancer research and development programs will be conducted in the United States by its subsidiary, OncoCyte Corporation.

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   BioTime, Inc.
                                                                                        440 Wheelers Farms Road
                                                                                        Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in U.S. Dollars

                                 Wright Quality Rating:DCNN                                  Key Data

   BioTime, Inc. is a biotechnology company engaged in two areas of biomedical               Ticker:
   research and product development. The Company's first business segment is blood           BTX
   plasma volume expanders and related technology for use in surgery, emergency
   trauma treatment, and other applications. Its lead blood plasma expander product,         2010 Sales:
   Hextend, is a physiologically balanced intravenous solution used in the treatment of
                                                                                             3,680,300
   hypovolemia. Its second business segment is regenerative medicine. Regenerative
   medicine refers to therapies based on human embryonic stem (hES) cell technology
   designed to rebuild cell and tissue function lost due to degenerative disease or          Major Industry:
   injury. In October 2009, BioTime, Inc. initiated development programs for human           Drugs, Cosmetics & Health
   therapeutic applications of hES cells, focused primarily on the treatment of cancer,      Care
   ophthalmologic, skin, musculo-skeletal system, and hematologic diseases. Cancer
   research and development programs will be conducted in the United States by its           Sub Industry:
   subsidiary, OncoCyte Corporation.                                                         Ethical Drug Manufacturers
                       Stock Chart                                    Officers
                                                                     Chairman                Country:
                                                                 Alfred D. Kingsley          United States

                                                              Chief Executive Officer        Currency:
                                                                Dr. Michael D. West
                                                                                             U.S. Dollars

                                                         Senior Vice President, Chief
                                                                                             Fiscal Year Ends:
                                                         Operating & Chief Financial
                                                                   Officer                   December
                                                              Robert W. Peabody
                                                                                             Employees
                                                                                             36

                                                                                             Exchanges:
                                                                                             ASE

                                                                                             Share Type:
                                                                                             Common

                                                                                             Market Capitalization:
             Stock Price (9/2/2011): 4.55
                                                 
								
To top